AKT1 and diffuse large B-cell lymphoma: To prove that on-target effects of the selected compounds were responsible for the differential killing of DLBCL cell lines, we performed competitive proliferation assays for which ten DLBCL cell lines were subjected to genome editing of the loci that encode the three above-mentioned selected drug targets, i.e., dihydrofolate reductase (DHFR), Bcl-2 and the AKT isoforms 1–3.